SparingVision logo 300

  • Scientific Story
    • Key Dates
    • Key Publications
  • SPVN06
  • About retinitis pigmentosa
  • People
    • Scientific Founders
    • Management
    • Board of directors
    • Scientific advisory board
  • Partners
    • Investors
    • Patient Advocacy Groups
  • News & Media
    • Press releases
    • In the News
  • Careers
  • Contacts
  • Slide
  • Slide
  • Our company

    We are a biotechnology company focused on the discovery and development of genomic medicines for the treatment of blinding inherited retinal diseases.

  • Our goal

    Bringing innovative treatments to physicians and patients to address serious ocular disorders.

  • Press release

    Thursday, 29 October 2020 08:00
    SparingVision Strengthens Management Team

SparingVision Raises €44.5 Million

  • Slide
  • Slide

 

 

About SPVN06

SPVN06 is a breakthrough treatment for retinitis pigmentosa, an orphan inherited retinal disease which leads to blindness and affects nearly two million people worldwide.

  • Slide
  • Slide

Read more

  • Retinitis pigmentosa

    A group of inherited retinal diseases which are a leading cause of blindness globally.

  • Scientific Discovery

    Over the last 20 years, the scientific founders of SparingVision have, with the support of other world leaders in the space, identified the relation between the survival of rods and the protection of cones, the latter being essential to preserve vision in retinitis pigmentosa patients.

  • Genomic Medicine

    Our lead product, SPVN06, is a gene therapy for the two synergetic isoforms of the NXNL1 gene (RdCVF and RdCVFL) into a single vector to treat patients who are experiencing degeneration of rods and partial vision loss.

SPVN06

Our lead product, SPVN06 is a breakthrough therapy for retinitis pigmentosa (RP), an orphan inherited retinal disease which leads to blindness and affects nearly two million individuals worldwide....

Read More ...

PEOPLE AFFECTED BY RETINITIS PIGMENTOSA

  • 70+

    MUTATIONS IN MORE THAN 70 GENES ARE KNOWN TO CAUSE RP

  • 2,000,000

    PEOPLE AFFECTED BY RP IN THE WORLD

  • 40,000

    PEOPLE AFFECTED BY RP IN FRANCE

Corporate presentation

  • Presentation of our company

    Download pdf

SPARINGVISION INVESTORS

Sparing vision BPIFrance

Sparingvision 4bioCapital

  • Scientific Story
    • Key Dates
    • Key Publications
  • SPVN06
  • About retinitis pigmentosa
  • People
    • Scientific Founders
    • Management
    • Board of directors
    • Scientific advisory board
  • Partners
    • Investors
    • Patient Advocacy Groups
  • News & Media
    • Press releases
    • In the News
  • Careers
  • Contacts
  • © SPARING VISION 2021 - All right reserved
  • Legal notice
Subscribe to newsletter